Zimbabwe has rejected a substantial US health deal worth 367 million US dollars (272 million pounds) over five years over Washington's demand for sensitive data.
This move was revealed after a official document from December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the deal was "lopsided".
An official spokesperson later stated that the United States was requesting biological samples for scientific study and commercial gain but was unwilling to guarantee the benefits from future medical innovations.
"We will now turn to the difficult and regrettable process of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for continued talks to find a deal agreeable to all parties so the nation's vital HIV programme can be sustained.
Wider Background
This development follows a comparable case in Kenya, where a high court blocked a related health funding agreement following concerns were raised about the security of citizens' health data.
Since resuming office last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump stated its expenditure was "inefficient" and his administration was seeking government-to-government deals to boost openness and accountability.
Based on statements, Sixteen nations in Africa have to date agreed to similar health pacts, constituting over $18.3bn in new funding.
Details of the Declined Deal
The funds for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership could have provided immense advantages for Zimbabwean communities, especially the 1.2 million presently on HIV treatment via American-funded initiatives," the Ambassador added.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, without any corresponding assurance of access to any medical innovations – such as new medicines or tests – that might be developed from that shared data," Mangwana explained.
"In essence, our nation would provide the basic resources for medical research with no certainty that the end products would be accessible to our population if a future pandemic arise."
Sovereignty and Global Health
He also said that the American exit from the global health body and its push of one-on-one health agreements were disrupting structures previously set up via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to deal with potential global health emergencies.
"This framework is intended to ensure that when a country provides its data, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We encourage continued discussions with our American counterparts on how future collaboration could be designed in a way that respects the sovereignty and interests of each country."
Medical Community Reaction
A leading public health body said it understood the official position, but suggested that talks must proceed given that a large portion of the country's HIV programmes were funded by foreign aid.
"Where technical issues arise, including those relating to data governance or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," it said.
This impasse highlights the complex debate between receiving vital foreign assistance and protecting local interests in an ever more interconnected world.